| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/10/2004 | WO2004076441A1 Process for producing acid adduct salt of polyacidic base compound |
| 09/10/2004 | WO2004076440A1 Polymorphs of s-omeprazole |
| 09/10/2004 | WO2004076437A1 Benzopyran compounds, process for preparing the same and their use |
| 09/10/2004 | WO2004076428A1 4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butane acid derivatives and related compounds as ppar modulators for treating diabetes of type 2 and atherosclerosis |
| 09/10/2004 | WO2004076427A1 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis |
| 09/10/2004 | WO2004076426A1 3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexanecarbonyl-amino butyric acid derivatives and related compounds as ppar modulators for the treatment of type 2 diabetes and atherosclerosis |
| 09/10/2004 | WO2004076423A1 Growth promotion method |
| 09/10/2004 | WO2004076417A1 Novel crystalline forms of trandolapril |
| 09/10/2004 | WO2004076416A1 Method of obtaining an antiepileptic agent |
| 09/10/2004 | WO2004076414A2 Novel compounds |
| 09/10/2004 | WO2004076412A2 Aminoheteroaryl compounds as protein kinase inhibitors |
| 09/10/2004 | WO2004076411A2 Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity |
| 09/10/2004 | WO2004076410A2 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
| 09/10/2004 | WO2004076407A2 Pyrrolidine derivatives as oxytocin antagonists |
| 09/10/2004 | WO2004076406A2 Losartan potassium polymorphs and process for the preparation thereof |
| 09/10/2004 | WO2004076402A1 Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments |
| 09/10/2004 | WO2004076401A1 Cycloalkyl-substituted alkanoic acid derivatives, methods for the production thereof, and use thereof as a medicament |
| 09/10/2004 | WO2004076349A1 Therapeutic malonic acid/acetic acid c60 tri-adducts of buckminsterfullerene and methods related thereto |
| 09/10/2004 | WO2004076011A2 System and method for facilitating play of a game with user-selected elements |
| 09/10/2004 | WO2004075990A1 Manganese based organometallic complexes, pharmaceutical compositions and dietetic products |
| 09/10/2004 | WO2004075921A1 Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
| 09/10/2004 | WO2004075920A1 Sustained-release pharmaceutical composition for lung administration |
| 09/10/2004 | WO2004075919A2 Compounds for protein stabilization and methods for their use |
| 09/10/2004 | WO2004075917A1 Organ or tissue fibrosis inhibitor |
| 09/10/2004 | WO2004075916A1 Pharmaceutical composition for treatment of drug dependence |
| 09/10/2004 | WO2004075915A1 Remedies for allergic contact dermatitis |
| 09/10/2004 | WO2004075908A1 Therapeutics for muscular dystrophy and therapeutic foods therefor |
| 09/10/2004 | WO2004075905A1 Muscle-building agent and preventive or remedy for muscle weakening |
| 09/10/2004 | WO2004075904A1 Method for treating liver cancer by intrahepatic administration of nemorubicin |
| 09/10/2004 | WO2004075903A1 Combined use of ribavirin and interferon beta in demyelinating diseases |
| 09/10/2004 | WO2004075902A1 Use of silicon derivatives of venlafaxine for the treatment or prevention of psoriasis or panic disorder |
| 09/10/2004 | WO2004075900A2 Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent |
| 09/10/2004 | WO2004075899A1 A method of prevention of lysosomal leakage in eukaryotic cells by using 6-methyluracil based water-soluble compounds and method of producing and use thereof |
| 09/10/2004 | WO2004075898A1 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| 09/10/2004 | WO2004075897A1 Pten inhibitor or maxi-k channels opener |
| 09/10/2004 | WO2004075896A1 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients |
| 09/10/2004 | WO2004075895A1 Ocular hypotensive agent |
| 09/10/2004 | WO2004075894A1 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride |
| 09/10/2004 | WO2004075893A1 Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker |
| 09/10/2004 | WO2004075892A2 Combination therapy for hypertension using lercanidipine and an angiotensin ii receptor blocker |
| 09/10/2004 | WO2004075891A1 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups, corresponding production method and use of said derivatives as medicaments |
| 09/10/2004 | WO2004075890A1 Medicinal composition containing stabilized imidazole derivative and method of stabilizing imidazole derivative |
| 09/10/2004 | WO2004075888A1 Remedy for corneal ulcer |
| 09/10/2004 | WO2004075887A1 Use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea for the treatment of pancreatic cancer, soft-tissue sarcoma, testicular tumors, lymphoma, thymoma, wilm's tumors, renal carcinoma, melanoma, lung cancer, intracerebral metastasis, tumors in the head and neck region, and mammary carcinoma |
| 09/10/2004 | WO2004075886A1 Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
| 09/10/2004 | WO2004075884A1 Therapeutic compositions |
| 09/10/2004 | WO2004075883A1 Use of curcumin derivatives or cape in the manufacture of a medicament for the treatment of neuroprotective disorders |
| 09/10/2004 | WO2004075882A1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 09/10/2004 | WO2004075881A1 Stable pharmaceutical composition of rabeprazole and processes for their preparation |
| 09/10/2004 | WO2004075879A1 Opioid delivery system |
| 09/10/2004 | WO2004075874A1 Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides |
| 09/10/2004 | WO2004075865A2 Selective modulation of tlr-mediated biological activity |
| 09/10/2004 | WO2004075864A2 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 09/10/2004 | WO2004075863A2 Cxcr3 antagonists |
| 09/10/2004 | WO2004075859A2 Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor |
| 09/10/2004 | WO2004075857A2 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| 09/10/2004 | WO2004075856A2 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases |
| 09/10/2004 | WO2004075854A2 Microbicidal compositions and method of use |
| 09/10/2004 | WO2004075853A2 Halogenated triptolide derivatives as immunomodulators and anticancer agents |
| 09/10/2004 | WO2004075852A2 Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions |
| 09/10/2004 | WO2004075850A2 Polyvalent immunogen |
| 09/10/2004 | WO2004075849A2 Method and composition for treating hypopigmentation of the hair and skin |
| 09/10/2004 | WO2004075848A2 Antitumor inhibitors and use thereof |
| 09/10/2004 | WO2004075846A2 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| 09/10/2004 | WO2004075845A2 Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents |
| 09/10/2004 | WO2004075844A2 Formulation for use in the prevention and treatment of carbohydrate induced diseases and conditions |
| 09/10/2004 | WO2004075840A2 Selective non-steroidal glucocorticoid receptor modulators |
| 09/10/2004 | WO2004075834A2 Stabilized pharmaceutical compositions of safingol and methods of using the same |
| 09/10/2004 | WO2004075832A2 Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof |
| 09/10/2004 | WO2004075828A2 Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation |
| 09/10/2004 | WO2004075825A2 Dosage forms of amlodipine and processes for their preparation |
| 09/10/2004 | WO2004075824A2 Pharmaceutical compositions for nasal delivery |
| 09/10/2004 | WO2004075817A2 Suspendable pharmaceutical composition |
| 09/10/2004 | WO2004075816A2 Method for the production of flavonoid-containing compositions and use thereof |
| 09/10/2004 | WO2004075815A2 Diarylcycloalkyl derivatives, method for their production and their use as medicaments |
| 09/10/2004 | WO2004075811A2 Subcutaneously-administered ganglioside-based vaccine compositions |
| 09/10/2004 | WO2004075781A2 Bioactive stents and methods for use thereof |
| 09/10/2004 | WO2004075775A2 Treatment of excessive osteolyisis with indolinone compounds |
| 09/10/2004 | WO2004075724A2 Serotonin and catecholamine system segment optimization technology |
| 09/10/2004 | WO2004065358A3 Method of reducing toxicity of retinoids |
| 09/10/2004 | WO2004064850A8 Antiviral composition comprising a sulphated glucose polymer and a bacteriostatic agent |
| 09/10/2004 | WO2004064749A3 Compositions for the reduction of hair growth |
| 09/10/2004 | WO2004062564A3 Sedative non-benzodiazepine formulations |
| 09/10/2004 | WO2004060362A3 COMPOSITIONS AND METHODS FOR INHIBITING TGF-β |
| 09/10/2004 | WO2004060263A3 Magnesium salt of imidazole derivative |
| 09/10/2004 | WO2004060261A3 Novel factor viia inhibiting compounds |
| 09/10/2004 | WO2004056348A3 Natural vitamin e compositions with superior antioxidant potency |
| 09/10/2004 | WO2004056336A3 Controlled release, multiple unit drug delivery systems |
| 09/10/2004 | WO2004054957A3 Valproic acid analogues and pharmaceutical compositions thereof |
| 09/10/2004 | WO2004054565A8 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 09/10/2004 | WO2004053087A3 Nf-κb inhibitors |
| 09/10/2004 | WO2004052847A3 Tricyclic steroid hormone nuclear receptor modulators |
| 09/10/2004 | WO2004050643A3 Non-nucleoside reverse transcriptase inhibitors |
| 09/10/2004 | WO2004050616A3 Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines |
| 09/10/2004 | WO2004050101A3 Formulations useful against hepatitis c virus infections |
| 09/10/2004 | WO2004047795A3 Cutaneous application of flupirtine |
| 09/10/2004 | WO2004045579A3 Pharmaceutical compositions and dosage forms of thalidomide |
| 09/10/2004 | WO2004043392B1 Mucin synthesis inhibitors |
| 09/10/2004 | WO2004043359A3 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor |
| 09/10/2004 | WO2004043357A3 Method of making, and the use of cytotoxic agents containing elemental selenium |